Novasep, a leading supplier of services and technologies for the life sciences industry, today announces that it has entered into an agreement with Celladon, a clinical-stage biotechnology company. Novasep will prepare to supply the drug substance for MYDICAR®.
Novasep’s extended presence in South East Asia strengthens the company’s ability to address growing needs in the region’s food and feed markets.
Novasep Varicol high-performance continuous chromatography technology brings productivity gains in an Indian-based API commercial production.
Pompey, October 2, 2014: Novasep, a leading supplier of manufacturing solutions to the life sciences industry, announces that it has completed the sale of the Bahamian facility and related business of its fully-owned subsidiary, Pharmachem Technologies (Grand Bahama) Ltd (Pharmachem), to a local investor.
Novasep wins approval to produce new molecular entity for US market.
The plant will enable Vietnam to domestically produce sorbitol, a sugar substitute it currently imports.
The new Highly Potent API (HPAPI) manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.
France, March 27th, 2014 - Novasep, a leading supplier of manufacturing solutions to Life Science industries, today announces its unaudited consolidated results1 for the period ended December 31st, 2013.
Pompey, France, March 4, 2014 - Novasep, a leading provider of global manufacturing solutions for life science molecules and fine chemicals, today announces the appointment of Michel Spagnol as chairman of the Supervisory Board, following the departure of Roger-Marc Nicoud, the founder of the group. Novasep provides an update of its strategic projects.
Thierry Van Nieuwenhove, a seasoned CMO top executive, joins Novasep as president of the Synthesis Business Unit.